作者
Baruch Modan, Patricia Hartge, Galit Hirsh-Yechezkel, Angela Chetrit, Flora Lubin, Uzi Beller, Gilad Ben-Baruch, Amiram Fishman, Joseph Menczer, Jeffery P Struewing, Margaret A Tucker, Sara M Ebbers, Eitan Friedman, Benjamin Piura, Sholom Wacholder
发表日期
2001/7/26
期刊
New England Journal of Medicine
卷号
345
期号
4
页码范围
235-240
出版商
Massachusetts Medical Society
简介
Background
Multiparity and the use of oral contraceptives reduce the risk of ovarian cancer, but their effects on this risk in women with a BRCA1 or BRCA2 mutation are unclear.
Methods
We conducted a population-based case–control study of ovarian cancer among Jewish women in Israel. Women were tested for the two founder mutations in BRCA1 and the one founder mutation in BRCA2 that are known to be common among Jews. We estimated the effects of parity and oral-contraceptive use on the risk of ovarian cancer in carriers and noncarriers in separate analyses that included all control women, who did not have ovarian cancer.
Results
Of 751 controls who underwent mutation analysis, 13 (1.7 percent) had a BRCA1 or BRCA2 mutation, whereas 244 of 840 women with ovarian cancer (29.0 percent) had a BRCA1 or BRCA2 mutation. Overall, each additional birth and each additional year of use of oral …
引用总数
学术搜索中的文章
B Modan, P Hartge, G Hirsh-Yechezkel, A Chetrit… - New England Journal of Medicine, 2001